Literature DB >> 33177192

A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.

Xingui Tian1, Shelby Landreth1,2, Yao Lu1, Kannupriya Pandey1,2, Yan Zhou3,2,4.   

Abstract

The recent highly pathogenic avian influenza (HPAI) H5N1 and H7N9 viruses have caused hundreds of human infections with high mortality rates. Although H5N1 and H7N9 viruses have been limited mainly to avian species, there is high potential for these viruses to acquire human-to-human transmission and initiate a pandemic. A highly safe and effective vaccine is needed to protect against a potential H5N1 or H7N9 influenza pandemic. Here, we report the generation and evaluation of two reassortant influenza viruses, PR8-H5-H7NA and PR8-H7-H5NA These viruses contain six internal segments from A/Puerto Rico/8/1934 (PR8), the HA segment from either A/Alberta/01/2014 (H5N1) [AB14 (H5N1)] or A/British Columbia/01/2015 (H7N9) [BC15 (H7N9)], and a chimeric NA segment with either the BC15 (H7N9) HA gene or the AB14 (H5N1) HA gene flanked by the NA packaging signals of PR8. These viruses expressed both H5 and H7 HAs in infected cells, replicated to high titers when exogenous NA was added to the culture medium in vitro, and were replication defective and nonvirulent when administered intranasally in mice. Moreover, intranasal vaccination with PR8-H5-H7NA elicited robust immune responses to both H5 and H7 viruses, conferring complete protection against both AB14 (H5N1) and BC15 (H7N9) challenges in mice. Conversely, vaccination with PR8-H7-H5NA only elicited robust immune responses toward the H7 virus, which conferred complete protection against BC15 (H7N9) but not against AB14 (H5N1) in mice. Therefore, PR8-H5-H7NA has strong potential to serve as a vaccine candidate against both H5 and H7 subtypes of influenza viruses.IMPORTANCE Avian influenza H5N1 and H7N9 viruses infected humans with high mortality rates. A highly safe and effective vaccine is needed to protect against a potential pandemic. We generated and evaluated two reassortant influenza viruses, PR8-H5-H7NA and PR8-H7-H5NA, as vaccine candidates. Each virus contains one type of HA in segment 4 and the other subtype of HA in segment 6, thereby expressing both H5 and H7 subtypes of the HA molecule. The replication of viruses is dependent on the addition of exogenous NA in cell culture and is replication defective in vivo Vaccination of PR8-H5-H7NA virus confers protection to both H5N1 and H7N9 virus challenge; conversely, vaccination of PR8-H7-H5NA provides protection only to H7N9 virus challenge. Our data revealed that when engineering such a virus, the H5 or H7 HA in segment 6 affects the immunogenicity. PR8-H5-H7NA has strong potential to serve as a vaccine candidate against both H5 and H7 subtypes of influenza viruses.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  H5N1 and H7N9 influenza virus; H5N1 and H7N9 virus; influenza A virus; replication-defective virus vaccine

Mesh:

Substances:

Year:  2021        PMID: 33177192      PMCID: PMC7925100          DOI: 10.1128/JVI.02154-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Packaging of influenza virus genome: robustness of selection.

Authors:  Takeshi Noda; Yoshihiro Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

2.  Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles.

Authors:  Tokiko Watanabe; Shinji Watanabe; Gabriele Neumann; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K.

Authors:  Yeun-Kyung Shin; Qiang Liu; Suresh K Tikoo; Lorne A Babiuk; Yan Zhou
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

4.  Biological sex affects vaccine efficacy and protection against influenza in mice.

Authors:  Ashley L Fink; Kyrra Engle; Rebecca L Ursin; Wan-Yee Tang; Sabra L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

5.  Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus.

Authors:  E C Claas; A D Osterhaus; R van Beek; J C De Jong; G F Rimmelzwaan; D A Senne; S Krauss; K F Shortridge; R G Webster
Journal:  Lancet       Date:  1998-02-14       Impact factor: 79.321

6.  Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus.

Authors:  Yao Lu; Shelby Landreth; GuanQun Liu; Robert Brownlie; Amit Gaba; Sylvia van Drunen Littel-van den Hurk; Volker Gerdts; Yan Zhou
Journal:  Vaccine       Date:  2020-01-31       Impact factor: 3.641

7.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

Review 8.  Influenza hemagglutinin and neuraminidase membrane glycoproteins.

Authors:  Steven J Gamblin; John J Skehel
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

Review 9.  Influenza.

Authors:  Florian Krammer; Gavin J D Smith; Ron A M Fouchier; Malik Peiris; Katherine Kedzierska; Peter C Doherty; Peter Palese; Megan L Shaw; John Treanor; Robert G Webster; Adolfo García-Sastre
Journal:  Nat Rev Dis Primers       Date:  2018-06-28       Impact factor: 52.329

Review 10.  Avian Influenza A Virus Pandemic Preparedness and Vaccine Development.

Authors:  Rory D de Vries; Sander Herfst; Mathilde Richard
Journal:  Vaccines (Basel)       Date:  2018-07-25
View more
  1 in total

Review 1.  Development and application of reverse genetic technology for the influenza virus.

Authors:  Ziquan Li; Liping Zhong; Jian He; Yong Huang; Yongxiang Zhao
Journal:  Virus Genes       Date:  2021-02-02       Impact factor: 2.332

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.